Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Dec;88(12):1563-7.
doi: 10.1136/bjo.2003.033498.

The relation between c-myc expression and interferon sensitivity in uveal melanoma

Affiliations

The relation between c-myc expression and interferon sensitivity in uveal melanoma

P N Tulley et al. Br J Ophthalmol. 2004 Dec.

Abstract

Background/aim: Interferons (IFN) are currently being used to treat melanoma, including some patients with uveal melanoma. IFN is thought to inhibit tumour growth through downregulation of the c-myc oncogene; the overexpression of which has been shown to be associated with resistance in cell lines. The aim of this study was to investigate the relation between c-myc gene expression and IFN sensitivity in a series of uveal melanomas in a short term chemosensitivity assay.

Methods: Tumours from 45 patients with uveal melanoma who had undergone enucleation were studied. The ATP chemosensitivity assay was used to study sensitivity to IFN-alpha-2b in freshly isolated cells from each tumour. Flow cytometry was used to assess c-myc expression in formalin fixed material from the primary specimens.

Results: There was a wide range of IFN sensitivity between the specimens whereas c-myc expression was universal and present in 80% of the tumour cells in 80% of the specimens. Higher c-myc expression was associated with IFN-alpha resistance as measured by the maximum percentage of inhibition (p = 0.05) and there was a trend with the IFN sensitivity index (p = 0.07).

Conclusions: These results demonstrate that tumours with high c-myc expression are also associated with IFN resistance. Future research is required to explore the potential of c-myc gene manipulation combined with IFN therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Typical dose-response curves of uveal melanoma cells to interferon alfa (IFN-α).
Figure 2
Figure 2
The distribution of (top) sensitivity index to interferon alfa (IFN-α) and (bottom) maximal percentage inhibition among the 45 uveal melanoma tumours in this study.
Figure 3
Figure 3
The distribution of c-myc oncoprotein positivity within the 45 tumours in this study.
Figure 4
Figure 4
The association between c-myc positivity and maximal percentage growth inhibition (top) and interferon alfa sensitivity index (bottom). The symbol represents the mean value in each group while the bars are the standard deviation.

Similar articles

Cited by

References

    1. Woll E , Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999;9:575–81. - PubMed
    1. Pyrhonen S . The treatment of metastatic uveal melanoma. Eur J Cancer 1998;34 (Suppl 3) :S27–30. - PubMed
    1. Nathan FE, Berd D, Sato T, et al. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997;16:201–8. - PubMed
    1. Pyrhonen S , Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 2002;95:2366–72. - PubMed
    1. Cree IA. Cytokine therapy and ocular melanoma. In: Zierhut M, Jager MJ, Ksander BR, eds. Immunology of ocular tumours. Lisse: Swets and Zeitlinger, 2002:147–55.

Publication types

MeSH terms